Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: Relevance to novel analogs

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 6, 2007, Pages

  Cozma, Irina ^a   Zhang, Lei ^a   Uddin, James ^b   Lane, Carol ^a   Rees, Aled ^a   Ludgate, Marian ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Adipogenesis; Somatostatin analogs

Indexed keywords

OCTREOTIDE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; THYROTROPIN RECEPTOR;

ADIPOCYTE; ADIPOGENESIS; ADULT; AGED; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; EX VIVO STUDY; FEMALE; HUMAN; IN VITRO STUDY; LYMPHOCYTE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADIPOCYTES; ADOLESCENT; ADULT; AGED; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GENE EXPRESSION; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; ORBIT; PPAR GAMMA; RECEPTORS, SOMATOSTATIN; RECEPTORS, THYROTROPIN; SOMATOSTATIN; T-LYMPHOCYTES; TRANSFECTION;

EID: 37149004020     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00177.2007     Document Type: Article

References (25)

1. Baker GR, Morton M, Rajapaska RS, Bullock M, Gullu S, Mazzi B, Ludgate M. Altered tear composition in smokers and patients with graves ophthalmopathy. Arch Ophthalmol 124: 1451-1456, 2006.
2. Chang TC, Liao SL. Slow-release lanreotide in Graves' ophthalmopathy. A double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 29: 413-422, 2006.
3. Crisp MS, Starkey KJ, Lane C, Ham J, Ludgate M. Adipogenesis in thyroid eye disease. Invest Ophthalmol 41: 3249-3255, 2000.
4. Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 89: 5910-5915, 2004.
5. Fuhrer D, Lewis MD, Alkhafaji F, Starkey K, Paschke R, Wynford-Thomas D, Eggo M, Ludgate M. Biological activity of activating thyroid-stimulating hormone receptor mutants depends on the cellular context. Endocrinology 144: 4018-4030, 2003.
6. Gaudillere A, Bernard C, Abello J, Schmitt D, Claudy A, Misery L. Human normal dermal fibroblasts express somatostatin receptors. Exp Dermatol 8: 267-273, 1999.
7. Gerding MM, van der Zant FM, van Royen EA, Koornneef L, Krenning EP, Wiersinga WM, Prummel MF. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 50: 373-379, 1999.
8. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 52: 267-271, 2000.
9. Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 42: 571-580, 1995.
10. Kumar S, Coenen MJ, Scherer PE, Bahn RS. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 89: 930-935, 2004.
11. Kung AW, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 6: 381-384, 1996.
12. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns CA. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding, and superior therapeutic potential. J Med Chem 46: 2334-2344, 2003.
13. Ludgate M, Baker G. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol 127: 193-198, 2002.
14. Pasquali D, Vassallo P, Esposito D, Bonavolonta G, Bellastella A, Sinisi AA. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 25: 63-71, 2000.
15. Pasquali D, Notaro A, Bonavolonta' G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. J Clin Endocrinol Metab 87: 5125-5129, 2002.
16. Pasquali D, Rossi V, Bellastella G, Esposito D, Quinto MC, Bellastella A, Sinisi AA. Antiproliferative effects of SOM230 on orbital fibroblasts from active Graves' ophthalmopathy (Abstract). Endocrine Abstracts 11: P939, 2006.
17. Postema PT, Krenning EP, Wijngaarde R, Kooy PP, Oei H, van den Bosch WA, Reubi JC, Wiersinga WM, Hooijkaas H, van der Loos T, Poublon RM, Lamberts SW, Henneman G. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J Clin Endocrinol Metab 79: 1845-1851, 1994.
18. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24: 802-835, 2003.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual (2nd ed.). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
20. Seboek D, Linscheid P, Zulewski H, Langer I, Christ-Crain M, Keller U, Muller B. Somatostatin is expressed and secreted by human adipose tissue upon infection and inflammation. J Clin Endocrinol Metab 89: 4833-4839, 2004.
21. Stan MN, Garrity JA, Bradley EA, Woog JJ, Bahn MM, Brennan MD, Bryant SC, Achenbach SJ, Bahn RS. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 91: 4817-4824, 2006.
22. Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S, Ludgate M. Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidenedione use? J Clin Endocrinol Metab 88: 55-59, 2003.
23. Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotropin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 30: 369-380, 2003.
24. Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387-389, 2006.
25. Zhang L, Baker G, Janus D, Paddon C, Fuhrer D, Ludgate M. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci 47: 5197-5203, 2006.